Showing 4211-4220 of 10627 results for "".
Discussing the Complications of IBS Mimickers
https://reachmd.com/programs/gi-insights/discussing-the-complications-of-ibs-mimickers/24057/What are IBS mimickers? Tune in.Recognizing and Addressing Burnout Among GI Providers
https://reachmd.com/programs/gi-insights/recognizing-and-addressing-burnout-among-gi-providers/26914/Here’s what you should know about recognizing and treating burnout, particularly in gastrointestinal healthcare.Reviewing the Treatment Landscape for Duchenne Muscular Dystrophy
https://reachmd.com/programs/neurofrontiers/reviewing-the-treatment-landscape-for-duchenne-muscular-dystrophy/16066/Although there is currently no cure, what treatment options are available for our patients with Duchenne muscular dystrophy?Managing MS in Older Adults: Key Considerations for DMTs and Lifestyle Interventions
https://reachmd.com/programs/frontlines-multiple-sclerosis/managing-ms-in-older-adults-key-considerations-for-dmts-and-lifestyle-interventions/32670/Tune in to hear experts discuss the unique challenges and considerations in managing multiple sclerosis in older adults.Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
https://reachmd.com/clinical-practice/cardiology/targeting-epicardial-adipose-tissue-in-patients-with-hfpef-without-diabetes-sotagliflozin-effect-from-sota-p-cardia-trial-sub-analysis/49274/Review SOTA-P-CARDIA sub-analysis findings on the effects of sotagliflozin on epicardial adipose tissue in patients with HFpEF without diabetes.Understanding Crossover and Endpoints in ASCENT-03 and -04
https://reachmd.com/programs/project-oncology/crossover-endpoints-ascent-03-04/48951/Knowing how crossover affects efficacy endpoints is key in interpreting clinical trial data for metastatic triple-negative breast cancer. The ASCENT-03 and -04 trials, which allowed crossover and tested sacituzumab govitecan in the first-line setting, offer insights into the limitations of overall sTreatment Revolution in IgA Nephropathy
https://reachmd.com/programs/kdigo-conversations-nephrology/treatment-revolution-in-iga-nephropathy/37116/Treatment Revolution in IgA NephropathyReimagining Autoimmune Care with CAR-Based Cell Therapies
https://reachmd.com/programs/living-rheum/reimagining-autoimmune-care-with-car-based-cell-therapies/32815/Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
https://reachmd.com/programs/project-oncology/are-subcutaneous-immunotherapies-expanding-access-and-efficiency-in-cancer-care/36401/Subcutaneous immunotherapies are emerging as a promising alternative to traditional IV delivery for immune checkpoint inhibitors, demonstrating comparable safety and efficacy along with meaningful time savings. But reimbursement gaps, dosing complexities, and biosimilar competition present challengeDebunking gMG Myths: Counseling Strategies That Change the Conversation
https://reachmd.com/programs/neurofrontiers/debunking-gmg-myths-counseling-strategies-that-change-the-conversation/35494/Misconceptions about disease progression and exercise are common among patients with generalized myasthenia gravis (gMG), especially early in their diagnosis. This underscores the importance of using relatable analogies and simplified explanations to help patients better understand their disease so